Abstract:Gene therapy has emerged as a promising approach for treating a wide range of genetic and acquired diseases by introducing or modifying genetic material within cells. To achieve successful gene therapy, efficient and precise delivery of genetic material, such as DNA or RNA, to target cells is essential. This abstract explores the development of both non-viral and viral vectors for the delivery of genetic material in gene therapy applications. Non-viral vectors, including lipid nanoparticles (LNPs), polymer-based carriers, and cell-penetrating peptides, have gained significant attention due to their safety profile and ease of production. These vectors are designed to protect genetic material from degradation, facilitate cellular uptake, and release the cargo at the desired location. Recent advancements in nanotechnology have enabled the design of customizable non-viral vectors with enhanced delivery efficiency and reduced offtarget effects. Viral vectors, on the other hand, harness the natural infectivity of viruses to transport genetic material into target cells. Retroviruses, lentiviruses, adenoviruses, and adeno-associated viruses (AAVs) are commonly used viral vectors in gene therapy. Viral vectors offer high transduction efficiency but may trigger immune responses or pose risks of insertional mutagenesis. Efforts in vector engineering have led to the development of safer viral vectors with improved targeting capabilities and reduced immunogenicity. AAVs, in particular, have gained prominence due to their ability to achieve long-lasting gene expression with minimal adverse effects. Targeted delivery strategies aim to enhance vector specificity, ensuring that genetic material reaches the intended cell type or tissue. These strategies include modifying vector surface proteins, employing tissue-specific promoters, or utilizing ligand-receptor interactions. In conclusion, the successful application of gene therapy relies on the development of efficient and targeted delivery systems for genetic material. Non-viral and viral vectors offer distinct advantages and continue to evolve to meet the demands of gene therapy applications. Advances in vector design, safety, and targeting strategies hold promise for the continued progress of gene therapy as a transformative medical intervention.

Biomaterial‐based gene therapy

Biomaterial-based Delivery of Nucleic Acids for Tissue Regeneration

Is Viral Vector Gene Delivery More Effective Using Biomaterials?

Bioinspired and Biomimetic Gene Delivery Systems

Bioactive Materials in Gene Therapy

Recent Advances of Biomaterials in Biotherapy.

Recent advances on two-dimensional material-based nanosystems for gene delivery

[Nanobiotechnological Gene Transfer Vectors in Gene Therapy].

Nanobiomaterial Vectors for Improving Gene Editing and Gene Therapy

Toxicity of Cationic Lipids and Cationic Polymers in Gene Delivery.

Non-viral vectors for gene-based therapy

Nanoplatform-Based in Vivo Gene Delivery Systems for Cancer Therapy.

Applications and Developments of Gene Therapy Drug Delivery Systems for Genetic Diseases

Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy

Developing non-viral or viral vectors for efficient and targeted delivery of genetic material, such as DNA or RNA, for gene therapy applications

Biocompatible polymers for gene delivery in cancer gene therapy

Non-viral Vectors in Gene Therapy: Recent Development, Challenges, and Prospects

Biomembrane-wrapped gene delivery nanoparticles for cancer therapy

Research Progress of nucleic acid delivery vectors for gene therapy

Advanced gene therapy system for the treatment of solid tumour: A review

Polymers as Efficient Non-Viral Gene Delivery Vectors: The Role of the Chemical and Physical Architecture of Macromolecules